Product
Glecaprevir + Pibrentasvir
Aliases
ABT-493/ABT-530, Glecaprevir and Pibrentasvir, Glecaprevir/Pibrentasvir (GLE/PIB), Mavyret
Name
Mavyret
INN Name
Glecaprevir and Pibrentasvir
FDA Approved
Yes
8 clinical trials
1 organization
10 indications
1 document
Indication
Hepatitis C VirusIndication
Kidney FailureIndication
Hepatitis CIndication
Chronic Kidney DiseaseIndication
ChronicIndication
HIV InfectionIndication
HepatitisIndication
CirrhosisIndication
Kidney TransplantIndication
PTSDClinical trial
A Multicenter, Single-Arm Prospective Study to Evaluate Safety and Efficacy of GLE/PIB 8-Week Treatment in Adults and Adolescents With Acute Hepatitis C Virus (HCV) InfectionStatus: Active (not recruiting), Estimated PCD: 2024-09-16
Clinical trial
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) InfectionStatus: Completed, Estimated PCD: 2020-05-21
Clinical trial
QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/PibrentasvirStatus: Completed, Estimated PCD: 2023-08-31
Clinical trial
HCV Test and Treat Utilizing Simplified HCV Patient EducationStatus: Recruiting, Estimated PCD: 2027-10-01
Clinical trial
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)Status: Completed, Estimated PCD: 2023-05-18
Clinical trial
Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Strategic Therapeutic Intervention to Enhance Linkage to Care in People Who Inject DrugsStatus: Recruiting, Estimated PCD: 2025-02-12
Clinical trial
An Open Label, Proof of Concept Study to Evaluate the Feasibility and Safety of Kidney Transplant From HCV Positive Donors Into HCV Negative RecipientStatus: Completed, Estimated PCD: 2021-04-28
Clinical trial
Glecaprevir/Pibrentasvir for the Treatment of PTSDStatus: Recruiting, Estimated PCD: 2023-12-31
Document
DailyMed Label: MavyretOrganization
AbbVie Inc.